Evidence map›Paper›PMID 38664510›Full record

Observational studyHypertension research : official journal of the Japanese Society of Hypertension2024

Relationship between 2nd-generation angiotensin receptor blockers and the risk of hypotension in COVID-19 patients admitted to hospital.

Fumiki Yoshihara, Yasushi Matsuzawa, Kiyomasa Nakatsuka, Jin Kirigaya, Ichiro Takeuchi, Kazuo Kimura, Masaaki Konishi, Kouichi Tamura, Kazuki Fukui, Kengo Tsukahara and 22 more

Abstract readObservational StudyMulticenter Study
PubMed Publisher
In one paragraph

Observational study in Hypertension research : official journal of the Japanese Society of Hypertension, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Response to the correspondence: Rethinking angiotensin receptor blocker (ARB) use in COVID-19: a class-wide call for careful dosing.Hypertension research : official journal of the Japanese Society of Hypertension · 2025
    Article
  3. Rethinking angiotensin receptor blocker (ARB) use in COVID-19: a class-wide call for careful dosing.Hypertension research : official journal of the Japanese Society of Hypertension · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors at 16 institutions in 1 country.

Fumiki YoshiharaDivision of Nephrology and Hypertension, National Cerebral and Cardiovascular Center, Osaka, Japan. fyoshi@ncvc.go.jp.
Yasushi MatsuzawaDivision of Cardiology, Yokohama City University Medical Center, Yokohama city, Japan.
Kiyomasa NakatsukaDepartment of Preventive Medicine and Epidemiology, National Cerebral and Cardiovascular Center Research Institute, Suita, Osaka, Japan.
Jin KirigayaDivision of Cardiology, Yokohama City University Medical Center, Yokohama city, Japan.
Ichiro TakeuchiAdvanced Critical Care and Emergency Center, Yokohama City University Medical Center, Yokohama City, Japan.
Kazuo KimuraDivision of Cardiology, Yokohama City University Medical Center, Yokohama city, Japan.
Masaaki KonishiDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Kouichi TamuraDepartment of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Kazuki FukuiDepartment of Cardiology, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.
Kengo TsukaharaDivision of Cardiology, Fujisawa City Hospital, Fujisawa, Japan.
Hiroyuki ShimizuDepartment of Clinical Laboratory Medicine, Fujisawa City Hospital, Fujisawa, Japan.
Keisuke IwabuchiDepartment of General Medicine, Kanagawa Prefectural Ashigarakami Hospital, Ashigara, Japan.
Yu YamadaDivision of Cardiology, Kanagawa Prefectural Ashigarakami Hospital, Ashigara, Japan.
Kenichiro SakaDivision of Cardiology, Yokosuka City Hospital, Yokosuka, Japan.
Yukihito SatoDepartment of Cardiology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.
Masahiro OgawaDepartment of Cardiology, Fukuoka University Hospital, Fukuoka, Japan.
Kayoko HayakawaDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Norio OhmagariDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Syuhei IkedaDepartment of Cardiology, National Hospital Organization Kyoto Medical Center, 1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, Japan.
Masaharu AkaoDepartment of Cardiology, National Hospital Organization Kyoto Medical Center, 1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto, Japan.
Hideki ShimomuraDivision of Cardiology, Fukuoka Tokushukai Hospital, Fukuoka, Japan.
Yasuki KiharaKobe City Medical Center General Hospital, 2-1-1, Minamimachi, Minatojima, Chuoku, Kobe, Hyogo, Japan.
Akihiro YoshimotoDepartment of Nephrology, Kobe City Medical Center General Hospital, Kobe, Japan.
Masanori MoritaCritical Care Medical Center Sakai City Medical Center, Sakai, Japan.
Norihiko KumadaDepartment of Urology, Suita Municipal Hospital, Suita, Japan.
Soshiro OgataDepartment of Preventive Medicine and Epidemiology, National Cerebral and Cardiovascular Center Research Institute, Suita, Osaka, Japan.
Kunihiro NishimuraDepartment of Preventive Medicine and Epidemiology, National Cerebral and Cardiovascular Center Research Institute, Suita, Osaka, Japan.
Tetsuya ArisatoDivision of Nephrology and Hypertension, National Cerebral and Cardiovascular Center, Osaka, Japan.
Miki MatsuoDivision of Nephrology and Hypertension, National Cerebral and Cardiovascular Center, Osaka, Japan.
Masatsugu KishidaDivision of Nephrology and Hypertension, National Cerebral and Cardiovascular Center, Osaka, Japan.
Satoshi YasudaDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.
Hisao OgawaKumamoto University, Kumamoto, Japan.
National Cerebral and Cardiovascular Center · JPYokohama City University · JPFujisawa City Hospital · JPKobe City Medical Center General Hospital · JPKyoto Medical Center · JPNational Center for Global Health and Medicine · JPYokohama City University Medical Center · JPFukuoka Tokushukai Hospital · JPFukuoka University Hospital · JPHiratsuka City Hospital · JPHyogo Prefectural Amagasaki General Medical Center · JPKanagawa Cardiovascular and Respiratory Center · JPKumamoto University · JPSakai Municipal Hospital · JPSuita Municipal Hospital · JPTohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It has not yet been established whether angiotensin II receptor blockers (ARB), statins, and multiple drugs affect the severity of COVID-19. Therefore, we herein performed an observational study on the effects of 1st- and 2nd-generation ARB, statins, and multiple drugs, on COVID-19 in patients admitted to 15 Japanese medical facilities. The results obtained showed that ARB, statins, and multiple drugs were not associated with the primary outcome (odds ratio: 1.040, 95% confidence interval: 0.688-0.571; 0.696, 0.439-1.103; 1.056, 0.941-1.185, respectively), each component of the primary outcome (in-hospital death, ventilator support, extracorporeal membrane oxygenation support, and admission to the intensive care unit), or the secondary outcomes (oxygen administration, disturbed consciousness, and hypotension, defined as systolic blood pressure ≤90 mmHg). ARB were divided into 1st- and 2nd-generations based on their approval for use (before 2000 and after 2001), with the former consisting of losartan, candesartan, and valsartan, and the latter of telmisartan, olmesartan, irbesartan, and azilsartan. The difference of ARB generation was not associated with the primary outcome (odds ratio with 2nd-generation ARB relative to 1st-generation ARB: 1.257, 95% confidence interval: 0.613-2.574). The odd ratio for a hypotension as one of the secondary outcomes with 2nd-generation ARB was 1.754 (95% confidence interval: 1.745-1.763) relative to 1st-generation ARB. These results suggest that patients taking 2nd-generation ARB may be at a higher risk of hypotension than those taking 1st-generation ARB and also that careful observations are needed. Further studies are continuously needed to support decisions to adjust medications for co-morbidities.

Indexed as

Angiotensin Receptor AntagonistsCOVID-19HypotensionAgedAged, 80 and overCOVID-19 Drug TreatmentFemaleHospitalizationHumansHydroxymethylglutaryl-CoA Reductase InhibitorsJapanMaleMiddle AgedSARS-CoV-2Angiotensin Receptor AntagonistsHydroxymethylglutaryl-CoA Reductase InhibitorsAngiotensin II receptor blockerCOVID-19Multiple drugsStatins

Identifiers

PMID38664510
OpenAlexW4395671862

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.